Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 3 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Pricing and Reimbursement in India - Introduction | 6 | 1 |
| GBI Research Report Guidance | 6 | 1 |
| Pricing and Reimbursement in India - Overview | 7 | 7 |
| Introduction to Healthcare System in India | 7 | 1 |
| Healthcare Expenditure Highly Correlated with GDP | 7 | 2 |
| Estimated Public Health Spending as a Percentage of GDP | 9 | 1 |
| Health Expenditure per Capita | 9 | 1 |
| Out-of-Pocket Health Expenditure as a Percentage of Private Expenditure on Health | 10 | 1 |
| Demographics by Age | 10 | 1 |
| Public Healthcare System | 11 | 1 |
| Drug Distribution in the Public Sector | 12 | 1 |
| Private Healthcare System | 12 | 1 |
| Rationale for Drug Use in the Healthcare Facilities | 13 | 1 |
| Pricing and Reimbursement in India- Overview of Pharmaceutical Regulations in India | 14 | 3 |
| PEST Analysis of the Pharmaceutical Industry in India | 14 | 1 |
| Regulatory Bodies in the Indian Pharmaceutical Sector | 15 | 1 |
| National Pharmaceutical Pricing Authority (NPPA) | 15 | 1 |
| Drug Prices Control Order (DPCO) | 16 | 1 |
| The Pharmaceutical Policy, 2002 | 16 | 1 |
| Pricing and Reimbursement in India- Pricing of Drugs | 17 | 20 |
| Introduction | 17 | 1 |
| Price Registration Process in India | 18 | 1 |
| International Price Comparison | 19 | 1 |
| Value-Based Pricing | 19 | 1 |
| Reference Pricing | 20 | 1 |
| Price Setting Procedures | 21 | 1 |
| Essential Drugs List (EDL) Pricing | 21 | 3 |
| Pricing Methodology for the Essential Drugs | 24 | 1 |
| Factors Determining the Pricing of the Drugs | 25 | 1 |
| Criteria for Selection of Drugs for Price Control | 26 | 1 |
| Pricing of Formulations | 27 | 1 |
| Annual Price Adjustments | 28 | 1 |
| Distribution of the Price Reduction Under National Pharmaceuticals Pricing Policy 2011 | 29 | 1 |
| Branded Generics Share | 30 | 1 |
| India-Specific Pricing | 31 | 1 |
| Pricing Approach to Patented Drugs | 32 | 1 |
| Selection of the Comparator Countries | 33 | 1 |
| Important Considerations while Fixing the Prices of the Patented Drugs | 33 | 1 |
| Pricing of the Orphan Drugs | 34 | 1 |
| Global Approach for Orphan Drug Development | 35 | 1 |
| Introduction of the Sales Ceiling and Flexible Market Exclusivity | 35 | 1 |
| Introduction of the Jan Aushadhi Shops | 36 | 1 |
| Pricing and Reimbursement in India - Reimbursement Scenario in India | 37 | 16 |
| Introduction | 37 | 1 |
| Health Insurance | 38 | 1 |
| Central Government Health Scheme | 39 | 1 |
| Employees State Insurance Scheme | 39 | 1 |
| Medical Reimbursement in India | 40 | 1 |
| Reimbursement Plans of Major Insurance Players | 40 | 1 |
| Oriental Insurance Company Limited | 40 | 1 |
| National Insurance Company Limited | 41 | 1 |
| New India Assurance Company Limited | 42 | 1 |
| Birla Sun Life Insurance | 43 | 1 |
| Private and Public Sector Insurance Companies in India | 43 | 1 |
| Reimbursement Policies in Other Countries | 44 | 1 |
| Out-of-Pocket (OOP) Expenditures | 45 | 1 |
| Co-Payment | 46 | 1 |
| Out-of-Pocket Expenditures in India | 47 | 1 |
| Comparison of OOP Expenditures | 48 | 1 |
| Irrational Drug Usage | 48 | 1 |
| Universal Health Care | 49 | 2 |
| Trends in Drug Reimbursement Policies | 51 | 1 |
| Health insurance Scenario in India | 52 | 1 |
| Challenges in Health Insurance | 52 | 1 |
| Pricing and Reimbursement in India - Conclusion | 53 | 1 |
| Pricing and Reimbursement in India - Appendix | 54 | 4 |
| Market Definitions | 54 | 1 |
| Abbreviations | 54 | 1 |
| Research Methodology | 54 | 3 |
| Coverage | 54 | 1 |
| Secondary Research | 55 | 1 |
| Primary Research | 55 | 1 |
| Overview | 55 | 1 |
| Overview of Pharmaceutical Regulations in India | 56 | 1 |
| Pricing of Drugs | 56 | 1 |
| Reimbursement Scenario in India | 56 | 1 |
| Expert Panels | 56 | 1 |
| Contact Us | 56 | 1 |
| Disclaimer | 56 | 1 |
| Sources | 57 | 1 |